Wilson's disease is a systemic disorder mainly aVecting the brain and liver. The lenticular nucleus is most severely aVected in the brain, and the name "hepatolenticular degeneration" reflects this pathological finding. 1 Neurological manifestations are varied, parkinsonism and dystonia being the most common. As striatal injury was classically described in pathological examination and was repeatedly shown on CT 2 3 and MRI, [4] [5] [6] [7] it has been thought to underlie the parkinsonism and dystonia. Furthermore single photon emission computerised tomography (SPECT) 8 and positron emission tomography (PET) 9 studies showed loss of D 2 receptors in the striatum. A report of poor response to levodopa in a case of Wilson's disease again supports a postsynaptic cause for the neurological manifestations. 10 Whereas there are the unequivocal reports of striatal or postsynaptic lesions, there are no pathological studies demonstrating damage in the substantia nigra. 1 11-13 However, there have been clinical and imaging studies suggesting nigral damage in Wilson's disease; the presence of levodopa responsiveness, 14 15 MR studies, [5] [6] [7] 
a [
18 F]-6-fluorodopa PET study, 16 and a [
11 C]-(+)-nomifensine PET study. 9 Therefore, we examined whether there is evidence of presynaptic nigrostriatal dopaminergic damage in Wilson's disease using dopamine transporter (DAT) imaging.
DAT is a protein located mainly in dopaminergic nerve terminals. 17 Nuclear imaging using ligands for DAT can measure its density. (1r)-2 -Carbomethoxy-3 -(4-iodophenyl)tropane ( -CIT) is a phenyltropane analogue of cocaine. It binds to DAT with high aYnity and low non-specific binding, and may be used as a radiopharmaceutical marker for nigrostriatal dopaminergic nerve terminals in the striatum. Pharmacological characterisation of regional binding disclosed high striatal binding in normal monkeys. 18 20 Radiochemical purity determined by thin layer chromatography was more than 95% and radiochemical yield was 65±10% (n=5). Apyrogenicity was confirmed by the limulus amebocite lysate test (Endosafe, Charleston, NC, USA). Sterility was confirmed by lack of growth in trypticase and fluid thioglycollate at 35°C for two weeks.
Antiparkinsonian medication in patients with Parkinson's disease was stopped for 48 hours before the study. All the patients with Wilson's disease were taking penicillamine. Two were taking zinc sulphate. No patients were taking dopaminergic medication for their neurological symptoms. Zinc sulphate was stopped for 48 hours before the study. Penicillamine was continued. Lugol solution (450 mg) was given to the patients and volunteers one day before the study. [
123 I]--CIT (370 MBq, 10 mCi) bolus injection was done over 30 seconds at 6 00 pm. The SPECT studies were performed using a double headed camera (Prism 2000, Picker, USA) equipped with a medium energy collimator. The patient was in a supine position on the table, and the head was positioned to obtain images in a plane parallel to the orbitomeatal line. The first scans were obtained at one and two hours after injection. On the next day, the images at 18, 21, and 24 hours after injection were obtained. Data were acquired with a 20% symmetric window centred at 159 keV, 128×128 matrix (pixel size 
Figure 1 [ 123 I]--CIT SPECT images of a normal control (A), a patient with Parkinson's disease(PD) (B), and a patient with Wilson's disease (WD) (C). See text for details.
4.67×4.67 mm, slice thickness 4.67 mm) and reconstructed with a Butterworth filter (cut oV 0.4 cycle/cm, order 7). For attenuation correction, Chang's method was used (µ 0.1/cm).
Reconstructed images were used to identify the brain anatomy and measure the radioactivity. Striatal and occipital regions of interest (ROIs) were visually positioned in the three contiguous slices of images showing the highest activity at the striatal region. Striatal ROI was of elliptical shape and of 5×7 pixel size (23.4×32.7 mm) to encompass the whole striatum ; and occipital ROI was positioned within each occipital area in a round shape of 6×6 pixels (28×28 mm). Radioactivities of striatal and occipital ROIs (expressed as counts/pixel/min) in the three slices were summed.
In the occipital lobe, the density of DAT is very low. 18 Specific striatal binding was defined as the striatal binding minus occipital binding. 
Results
The results from measurements at 18, 21, and 24 hours after injection were nearly the same. The results at 18 hours are described. (fig 1 (c) ), striatal binding was decreased bilaterally and more marked in the caudal part, which was similar to that seen in Parkinson's disease. Table 2 shows the specific S/O ratios derived from 18 hour images. In normal controls the specific S/O ratios ranged from 4.52 to 9.67 (mean (SD) 6.22 (1.32)). The ratios in patients with Parkinson's disease ranged from 2.68 to 4.35 (mean (SD 3.78 (0.65)) and the ratios in the Wilson's disease group ranged from 2.96 to 4.30 (mean (SD) 3.60 (0.49)). In all patients of the Wilson's disease and Parkinson's disease groups, specific binding ratios were below the range of the normal control group without overlap (fig 2) . The specific S/O ratios in the Wilson's disease group were significantly lower than normal control group (p<0.001). Values in the Wilson's disease group were not different from the Parkinson's disease group. The specific S/O ratios of normal controls tended to decline with age, as reported previously; 21 however, the result was non-significant with the small sample size in this study (r=−0.41, p=0.12). As the Wilson's disease group was younger than normal controls, the decrease in specific S/O ratio is not explained by age diVerence. 21 as seen in our study does not explain the decrease in DAT in patients withWilson's disease as they were younger than normal controls (mean age 30 in Wilson's disease, 40 in normal controls). When age matched, the specific S/O ratios in Wilson's disease were even lower than those of normal controls. Our data show that there is significant nigrostriatal dopaminergic damage in Wilson's disease. The severity of damage was comparable with that of patients with Parkinson's disease.
Discussion
Postsynaptic damage in the striatum has been repeatedly shown in pathological examination, 1 11-13 CT or MR images, 2-7 and D 2 receptor imaging. 8 9 Even though striatal injury has been well demonstrated in these studies, clinical correlation between neurological deficits and imaging studies was poor, suggesting that more than striatal lesions play a part in neurological deficits.
There is some evidence suggesting significant presynaptic nigral damage in neurological Wilson's disease. If parkinsonism in Wilson's disease is exclusively due to postsynaptic striatal injury, levodopa responsiveness would not be anticipated. But there are some reports of favourable responses to levodopa in the neurological symptoms of Wilson's disease. 14 15 MRI has shown that the distribution of structural changes in the brain is not limited to the striatum. [4] [5] [6] [7] High signal intensity lesions were found in the midbrain, including the nigral region, [5] [6] [7] and reversed with penicillamine. 7 The midbrain signal changes may suggest presynaptic lesions in dopaminergic nerves. In our patients with Wilson's disease with available MR images, all five patients had signal changes in the midbrain.
In a [
18 F]-6-fluorodopa PET study by Snow et al, 16 the fluorodopa uptake of four neurological patients with Wilson's disease was decreased in the striatum. Using a DAT ligand nomifensine Westermark et al 9 found reduced striatal binding of [ In conclusion, we showed a decrease of the DAT in the striatum in Wilson's disease indicating damage to nigrostriatal dopaminergic nerve terminals. There is an apparent incongruity between our data showing that DAT is severely decreased to the Parkinson's disease range in the striatum and pathological studies showing that there is no damage in the substantia nigra. 1 11-13 There may be two explanations for this incongruity. It may be that nigrostriatal dopaminergic damage in Wilson's disease occurs mainly in the nerve terminals but not in the cell body. It is interesting to note that the dopamine concentration was severely decreased in the striatum when there was no notable pathological change in the substantia nigra in an eight year old patient with Wilson's disease. 13 In another biochemical study, tyrosine hydroxylase activity was decreased in the striatum but not in the substantia nigra. 23 These biochemical data are consistent with our data which suggest a preferential damage in the nerve terminals in Wilson's disease. Another possibility is that DAT is down regulated. Haloperidol 24 and reserpine 25 decrease the striatal DAT, whereas cocaine 26 and mazindol 24 increase it. These data suggest that the DAT is subject to dopaminergic regulation, even though levodopa itself does not change the DAT. 24 Penicillamine and zinc sulphate were the only medications in the patients with Wilson's disease. Penicillamine and zinc sulphate do not have known dopaminergic action, thus are unlikely to regulate the DAT directly. However, the absence of direct information on penicillamine, zinc sulphate, and DAT makes it diYcult to completely rule out this possibility. It is known that DAT gene expression is increased by direct interaction with target striatal cells in culture of rat embryonic mesencephalic dopaminergic neurons. 27 Striatal injury in Wilson's disease may cause a loss of synaptic contact for nigrostriatal dopaminergic nerve terminals resulting in down regulation of the DAT and tyrosine hydroxylase. However, hypoxic-ischaemic striatal injury in the neonatal rat does not decrease striatal dopamine, 28 dopamine uptake sites measured by [ 3 H]mazindol binding, 28 TH immunostaining, 29 and in vivo tyrosine hydroxylase activity. 30 Nor does axon sparing striatal excitotoxic injury in the adult rat result in decreased tyrosine hydroxylase activity 31 and tyrosine hydroxylase immunostaining. 32 We interpret these data to mean that loss of postsynatic neurons in the striatum does not result in down regulation of the DAT and tyrosine hydroxylase at least after birth. Therefore, we favour the hypothesis that decrease of DAT in Wilson's disease is due to direct nerve terminal damage, not due to down regulation from postsynaptic striatal injury.
The degree of presynaptic damage measured by in vivo DAT imaging was comparable with that of Parkinson's disease, and may well have a profound influence on the neurological manifestations of Wilson's disease as well as postsynaptic lesions. The relative proportion of presynaptic and postsynaptic damage may explain conflicting reports of levodopa responsiveness.
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